Chemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to “Hold” Rating

Chemomab Therapeutics (NASDAQ:CMMB) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Wednesday. Oppenheimer lifted their target price on shares of Chemomab Therapeutics from $10.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $26.50.

Chemomab Therapeutics Trading Down 2.7%

Shares of CMMB opened at $3.28 on Friday. The firm’s 50-day moving average price is $3.21 and its 200-day moving average price is $4.24. The firm has a market capitalization of $16.96 million, a price-to-earnings ratio of -1.39 and a beta of 0.57. Chemomab Therapeutics has a 1-year low of $2.39 and a 1-year high of $9.84.

Chemomab Therapeutics (NASDAQ:CMMB) last announced its earnings results on Thursday, August 14th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.44. On average, research analysts forecast that Chemomab Therapeutics will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Chemomab Therapeutics stock. Virtu Financial LLC grew its position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 113.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 30,803 shares of the company’s stock after buying an additional 16,358 shares during the period. Virtu Financial LLC owned approximately 0.21% of Chemomab Therapeutics worth $34,000 as of its most recent SEC filing. 46.05% of the stock is owned by hedge funds and other institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).